Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Random

Display 45 Products per page

Disease Analysis: Type 2 Diabetes
Read More
Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.
October 20, 2021
Find out more
The Real Value of Medtech Markets: The impact of currency movements

$2,995.00

This report provides a comprehensive picture of the global medical orthopaedics market and relevant background, using the latest data and expert analysis. The report covers the top 160 markets by estimated US dollar value in 2019.
November 27, 2019
Find out more
Global Market for Fracture Fixation Devices

$4,750.00

This Meddevicetracker report provides an analysis of the market for fracture fixation devices, including external fixation and internal fixation devices. Geographic segments covered include the US, five major EU markets, Japan, and the rest of the world.The global fracture fixation devices market is expected to increase at a CAGR of 5.9% over the five-year forecast period, reaching nearly $11bn in 2023. Competition is increasing in fracture fixation, as major orthopedic suppliers enter the market to take advantage of cross-selling opportunities, and manufacturers from other specialties, such as arthroscopy and spine, launch new products.
August 28, 2019
Find out more
Alpelisib
Read More
Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Find out more
ITCA 650
Read More
ITCA 650 (exenatide; Intarcia Therapeutics/Servier) is a drug-device combination currently being investigated in Phase III trials for the treatment of type 2 diabetes.
November 7, 2017
Find out more
Multiple Sclerosis (MS) KOL Interview – US, Midwest

$599.00

In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.
March 2, 2020
Find out more
Entrectinib
Read More
Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
August 30, 2018
Find out more
Market Spotlight: Atopic Dermatitis

$1,318.00

This Market Spotlight report covers the Atopic Dermatitis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
August 18, 2020
Find out more
SaxaDapa
Read More
SaxaDapa is a fixed-dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT-2) inhibitor Farxiga (dapagliflozin; AstraZeneca) and dipeptidyl peptidase-IV inhibitor Onglyza (dapagliflozin; AstraZeneca/Kyowa Hakko Kirin).
November 7, 2017
Find out more
Zinbryta
Read More
Zinbryta is a humanized monoclonal antibody that selectively binds to the alpha chain (cluster of differentiation [CD]25) of the interleukin-2 receptor on activated T cells to prevent the immunoactivation of MS.
November 24, 2017
Find out more
Nucala
Read More
Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.
July 31, 2018
Find out more
Rytary
Read More
Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component.
June 21, 2018
Find out more
Aricept
Read More
Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
Alzheimer’s disease for more than a decade.
September 2, 2016
Find out more
Disease Analysis: Epilepsy
Read More
Epilepsy is characterized by recurrent, unprovoked seizures, and is one of the most common chronic neurological disorders globally. A seizure is a transient manifestation of signs and/or symptoms, including a disturbance of consciousness, emotion, behavior, or motor function, which occurs because of abnormal excessive or synchronous neuronal activity in the brain.
November 22, 2021
Find out more
Savaysa
Read More
Savaysa (edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
March 15, 2018
Find out more
Striverdi Respimat
Read More
Striverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler.
July 31, 2018
Find out more
Feraccru
Read More
Feraccru (ferric trimaltol; Shield Therapeutics/AOP Orphan Pharmaceuticals) is a novel oral ferric iron form with hematinic activity being investigated for the treatment of anemia in chronic kidney disease (CKD).
January 11, 2018
Find out more
Levemir
Read More
Levemir (insulin detemir; Novo Nordisk) is a long-acting basal insulin analog. It is indicated for the improvement of glycemic control in adults and children (aged two years and older) with type 1 diabetes or type 2 diabetes.
November 7, 2017
Find out more
Angiomax
Read More
Angiomax is a direct thrombin inhibitor which prevents the formation of fibrin from fibrinogen and the activation of coagulation factor XII.
April 14, 2016
Find out more
Inflammatory Bowel Disease (IBD) KOL Interview – US

$599.00

A US gastroenterology expert dives into the treatment algorithm, critical unmet needs, and pipeline drugs for IBD, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.
March 1, 2021
Find out more
Access in Emerging Markets: HTA is Making Inroads

$2,995.00

Generally considered the domain of developed markets, health technology assessment (HTA) is increasingly being used by developing countries as a means of reconciling growing demand for access to health technologies with limited resources. Expanding public health insurance programs, coupled with aging populations and growing patient empowerment, have led in some cases to the fast establishment […]
November 2, 2016
Find out more
Market Spotlight: Renal Disease

$1,318.00

This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
December 9, 2021
Find out more
Afinitor
Read More
Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.
March 6, 2019
Find out more
PT003
Read More
While PT003 (formoterol/glycopyrrolate; AstraZeneca) demonstrated statistically significant

improvements in trough forced expiratory volume in one second (FEV1) compared to its individual

components and placebo in its Phase III PINNACLE program, pulmonologists are unconvinced about its

role in symptom improvement.
April 8, 2016
Find out more
2015 Cancer Drug Pricing Surveys

$799.00

We performed two 5-question surveys of oncologists in the US to gauge the impact of cancer treatment costs on prescribed therapies.
August 10, 2015
Find out more
Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

$599.00

This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.
January 18, 2019
Find out more
Company Analysis: Boehringer Ingelheim

$3,000.00

PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include regular earnings coverage and provide timely updates to company product forecasts.
July 21, 2020
Find out more
Ninlaro
Read More
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.
August 9, 2018
Find out more
Duaklir Pressair
Read More
Duaklir Pressair ([aclidinium + formoterol]; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist formoterol and the long-acting muscarinic antagonist aclidinium.
July 31, 2018
Find out more
Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.
October 21, 2015
Find out more
Rebinyn
Read More
Rebinyn is a glycoPEGylated rebombinant factor IX (rfIX) therapy developed by Novo Nordisk for the treatment of hemophilia B.
May 20, 2018
Find out more
Global Radiation Therapy Systems Market, March 2016

$3,750.00

This report covers the large, highly competitive, technology driven Global Market for Radiation Therapy Systems—valued at nearly $4.3 billion in 2015.
March 1, 2016
Find out more
MDS/AML KOL Interview

$599.00

Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]
April 9, 2015
Find out more
APL-130277
Read More
APL-130277 (Dainippon Sumitomo/Sunovion) is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist.
June 21, 2018
Find out more
Enbrel
Read More
Enbrel (etanercept; Amgen/Pfizer/Takeda) is a dimeric fusion protein consisting of the extracellular ligand binding portion of tumor necrosis factor (TNF) receptor linked to the Fc portion of human immunoglobulin G1.
May 18, 2018
Find out more
Market Spotlight: Axial Spondyloarthritis (axSpA)

$1,318.00

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
December 9, 2021
Find out more
lisocabtagene maraleucel
Read More
Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market following the launches of approved CAR-T drugs Kymriah (tisagenlecleucel; Novartis) and Yescarta (axicabtagene ciloleucel; Gilead).
January 30, 2019
Find out more
Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries
November 1, 2012
Find out more
SGLT-2 Pulse Survey

$599.00

We surveyed primary care physicians (n=10) and endocrinologists (n=10) to see how SGLT-2 inhibitors and the combo pills will be used and what the potential impact of usage with GLP-1 agonists may have.
August 25, 2014
Find out more
Disease Analysis: Head and Neck Cancer
Read More
Head and neck cancers (HNCs) are defined as any cancer that begins in cells of the oral cavity, pharynx, nose, sinuses, or salivary glands. These cancers are grouped together due to historical similarities in etiology, disease presentation, and manifestation. The vast majority of these cases (90%), collectively referred to as head and neck squamous cell carcinomas (HNSCCs), appear in squamous epithelial cells lining the mucous membranes of these regions. The exception to this is salivary gland cancer, which can appear in any of the salivary glands’ diverse cell types.
November 22, 2021
Find out more
When Deals Go Wrong: Lessons from Failure

$2,995.00

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Yet a look back at prior years’ eye-popping deal sums reveals many billions of dollars of write-offs and lost value. Key assets failed or disappointed in at least half of 2014’s largest acquisitions and licensing deals. Failure is part of the drug discovery landscape, but some lessons can be learned from dud deals.

July 12, 2019
Find out more
Mirogabalin
Read More
Mirogabalin (Daiichi Sankyo) is an oral therapy that preferentially and selectively binds to the α2δ-1 (alpha-2 delta-1) subunit of calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.
May 31, 2018
Find out more
Rydapt
Read More
Rydapt is a multiple kinase inhibitor that interferes with cellular signal transduction pathways.
July 6, 2017
Find out more
Asciminib
Read More
Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) in development by Novartis for Philadelphia chromosome-positive diseases such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia.
December 7, 2017
Find out more
Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.
March 23, 2020
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *